Skip Navigation
Department of Health and Human Services www.hhs.gov
  • Home
  • Search for Research Summaries, Reviews, and Reports
 
 
Maintenance Notice
An infrastructure upgrade will take place on Friday, December 19 at approximately 2PM Eastern time. Please be aware you may experience temporary issues accessing the site at that point.

EHC Component

  • EPC Project

Full Report

Related Products for this Topic

Original Nomination

For free print copies of this summary, call 800-358-9295. Ask the Publications Clearinghouse for AHRQ Publication 11(12)-EHC-074-3
Save this page in Facebook.com  Save this page in Myspace.com  Save this page in Twitter.com  Save this page on your Google Home Page  Save this page in Windows Live
Save this page in Yahoo  Save this page in Ask.com  Stumble this page.  Save this page in del.ico.us  Digg this page. 

E-mail E-mail   Print Print

Add to My Collections



Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Clinician Summary – Apr. 9, 2012

Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Formats

Table of Contents

Focus of Research for Clinicians

In response to a request from the public, a systematic review of the clinical research was undertaken to determine what is known about the comparative effectiveness, benefits, and adverse effects of urinary incontinence (UI) interventions for women and the utility of methods for diagnosis and treatment evaluation. The systematic review included 905 publications presenting the results of clinical studies published from January 1990 through December 2011. The full report, listing all studies, is available at www.effectivehealthcare.ahrq.gov/ui.cfm. This summary, based on the full report of research evidence, is provided to clinicians to inform discussions of options with patients and to assist in decisionmaking along with consideration of a patient’s values and preferences. However, reviews of evidence should not be construed to represent clinical recommendations or guidelines.

Background

UI affects women of all ages, but its prevalence increases with age. The severity of the physical, psychological, and social burdens of UI can range from mildly bothersome to debilitating.

Two predominant forms of UI are stress incontinence (sphincter failure during increases in intra-abdominal pressure, as when coughing or sneezing or with exertion) and urgency incontinence (involuntary loss of urine accompanied by a compelling urge to void, often associated with bladder detrusor muscle overactivity). Both forms can appear in one individual as the “mixed” type. Patient reports of symptoms are the typical basis for diagnosing UI, after exclusion of underlying causes (e.g., infection, urogenital prolapse). Urodynamic evaluation is not typically used in primary care, but is used for differential diagnosis, especially for patients considering surgical treatment. The comparative reliability of diagnostic methods and their value for individualizing treatment are not well understood. Non-surgical treatments include lifestyle changes, pelvic floor muscle training (PFMT), bladder training, and drugs for urgency incontinence from overactive bladder. Effectiveness of UI interventions is typically measured by reduction in frequency of UI episodes and amounts of urine in absorbent pads, although the treatment goals valued by women with UI are not clearly established.

Conclusion

Nonpharmacological interventions (notably, PFMT or bladder training) lessen the severity of urgency, stress, and mixed UI, and promote continence in patients with stress and mixed UI, with low risk of adverse effects. For nonpharmacological interventions, reasons for discontinuation and methods to improve adherence are not understood or systematically investigated. Drug treatments for urgency UI show similar small benefits but may be differentiated by their adverse effects profiles. Withdrawal from drug treatment is typically due to adverse effects. Dry mouth and constipation are common. The long-term safety of drugs for UI has not been evaluated in clinical trials, but serious adverse effects have been associated with their use (e.g., among the elderly and in combination with other commonly prescribed drugs). Diagnosis using clinical tools available in primary care is comparable to urodynamic evaluation. Urodynamic evaluation is not associated with better outcomes with non-surgical treatments. Currently available validated tools (voiding diaries, scales measuring perception of improvement and quality of life) are effective for measuring success with treatment targets that are valued by women with UI.

Clinical Bottom Line

Diagnosis and Treatment Monitoring

Comparative Value of Methods for Diagnosis

  • Patient reports of individual symptoms of stress or urgency have minimal or small diagnostic value when compared with both urodynamics and clinical diagnosis. evidence high
  • Clinical algorithms for differentiating stress, urgency, and mixed UI (e.g., including a voiding diary and a cough stress test) have high diagnostic value when compared with urodynamics. evidence medium
  • Diagnosis by urodynamic examination is not associated with better outcomes with non-surgical treatments. evidence medium

Treatment Monitoring

  • Multiple validated instruments can be used to monitor treatment success by detecting meaningful changes in symptoms and quality of life (QoL), as identified by women with UI. evidence high
    • Clinical success is perceived by women when episode frequency is reduced by 50 percent or more.
    • QoL improvements are perceived by women at a 70 percent reduction in frequency (as measured by the Incontinence Quality of Life Questionnaire and the Global Perception of Improvement and Incontinence Impact Questionnaire).
Nonpharmacological Interventions

Benefits

  • Some nonpharmacological interventions can promote continence and improve severity for patients with stress, urgency, or mixed forms of UI, with limited risk of adverse effects. (See Table 1 for details.)
Strength of Evidence Scale

High: evidence high
There are consistent results from good-quality studies. Further research is very unlikely to change the conclusions.

Moderate: evidence medium
Findings are supported, but further research could change the conclusions.

Low: evidence low
There are very few studies, or existing studies are flawed.

Insufficient: evidence insufficient
Research is either unavailable or does not permit estimation of a treatment effect.

Table 1. Outcomes of Nonpharmacological Interventions for UI

The ability of interventions to achieve continence or clinically important improvement was compared with placebo or no active treatment. Meta-analytic results are presented as the number of reported events attributable to treatment per 1,000 patients (calculated from the difference between treatment-group and control-group event rates).

Indication Intervention Continence
(Reports
per 1,000
treated)
Improvement
(Reports
per 1,000
treated)
NSD = no statistically significant difference; NR = not reported
Stress UI PFMT 299 evidence high 412 evidence mediumevidence medium
PFMT plus biofeedback NSD evidence low 390 evidence high
Electrical stimulation 162 evidence high 156 evidence high
Magnetic stimulation NSD evidence medium 265 evidence medium
Urgency UI Bladder training evidence insufficient 430 evidence low
Percutaneous tibial nerve stimulation NR 308 evidence medium
Mixed UI PFMT plus bladder training 166 evidence high 387 evidence high
Maintained weight loss and exercise evidence insufficient 273 evidence medium
All training regimens of PFMT increase rates of continence and improvement in stress UI. evidence high
Comparative Effectiveness of Nonpharmacological Interventions

For Stress and Mixed UI

For Urgency UI

Pharmacological Interventions for Urgency UI

Benefits

Adverse Effects

Comparative Effectiveness of Pharmacological Interventions
  • When compared with tolterodine, fesoterodine achieves higher rates of continence (55 reports per 1,000 evidence low) and improvement (28 reports per 1,000 evidence high).
  • No statistically significant difference in improvement rates is found in comparisons of oxybutynin and tolterodine. evidence medium
  • Discontinuation rates due to adverse effects are higher with fesoterodine (a difference of 17 reports per 1,000 evidence medium) and oxybutynin (a difference of 71 reports per 1,000 evidence high) when compared with tolterodine.
  • No statistically significant difference in discontinuation rate was found in comparisons of solifenacin and tolterodineevidence medium
  • The evidence from other head-to-head comparisons reported in the literature is insufficient to permit conclusions about comparative benefits or adverse effects.
Modifiers of Pharmacological Treatment
  • Age does not modify continence or improvement outcomes of oxybutynin, trospium, or darifenacin. evidence medium
  • Trospium is more effective than placebo in both obese and nonobese women (evidence high). The effect of obesity on outcomes with other drugs is not known.
  • The effectiveness of trospium is not affected by concomitant medications, but adverse effects are more common when trospium is taken with seven or more concomitant medications. evidence medium
  • Solifenacin is effective regardless of response to previous treatment, even in those patients who did not respond to higher doses of other drugs. evidence high
  • Tolterodine and solifenacin outcomes are not affected by mixed or pure urgency types of UI. evidence medium
  • Patients with mixed UI may require a larger dose and longer treatment with solifenacin. evidence low
  • Baseline frequency of UI does not influence clinical outcomes of any drug. evidence low

Gaps in Knowledge

The systematic review identified areas where evidence about treatments for UI is limited or absent, including:

What To Discuss With Your Patients

  • The roles of nonpharmacological, pharmacological, and surgical interventions.
  • The trade-offs between the likelihood of benefits and the types and severity of adverse effects associated with UI drug treatments.
  • The importance of adherence to exercise protocols to achieve continence or improve severity of UI.
  • The benefits and low risk of adverse effects from nonpharmacological UI treatments, such as special exercises.

Resource for Patients

Non-surgical Treatments for Urinary Incontinence, A Review of the Research for Women is a free companion to this clinician research summary. It covers:

  • The types of UI and procedures for diagnosis
  • The types of drug and nondrug interventions that are available for treating stress, urgency, and mixed UI
  • The potential for benefits and the risks of adverse effects when drug or nondrug treatments are chosen
  • Questions to ask when making decisions about UI treatment options

Source

The information in this summary is based on Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness, Comparative Effectiveness Review No. 36, prepared by the Minnesota Evidence-based Practice Center under Contract No. 291-2007-10064-I for the Agency for Healthcare Research and Quality, April 2012. 

This summary was prepared by the John M. Eisenberg Center for Clinical Decisions and Communications Science at Baylor College of Medicine, Houston, TX. It was written by Diane Markesich, Ph.D., Aimee Roundtree, Ph.D., Thomas Workman, Ph.D., Ursula Braun, M.D., and Michael Fordis, M.D.  

Return to Top of Page